In vivo mutagenicity and mutation spectrum in the bone marrow and testes of B6C3F1 lacI transgenic mice following inhalation exposure to ethylene oxide. 2004

Leslie Recio, and Maria Donner, and Diane Abernethy, and Linda Pluta, and Ann-Marie Steen, and Brian A Wong, and Arden James, and R Julian Preston
CIIT Centers for Health Research, 6 Davis Drive, Research Triangle Park, NC 27709, USA. leslie_recio@merck.com

The lacI mutant frequency and mutation spectrum were determined in the bone marrow and testes of B6C3F1 lacI transgenic mice exposed by inhalation to ethylene oxide (EO). Groups of male transgenic lacI B6C3F1 mice were exposed to 0, 25, 50, 100 or 200 p.p.m. EO for up to 48 weeks (6 h/day, 5 days/week) and were killed at 12, 24 or 48 weeks of EO exposure for determination of lacI mutant frequency. In the bone marrow, the lacI mutant frequency was significantly increased at the two highest exposure levels (100 and 200 p.p.m.) and at the 48 week exposure time point. The shape of the exposure-response curve for lacI mutant frequency in the bone marrow was non-linear. DNA sequence analysis of the bone marrow mutation spectrum revealed that only AT-->TA transversions occurred at an increased frequency in EO-exposed mice: 25.4% in EO-exposed mice for 48 weeks (200 p.p.m.) compared with 1.4% in air controls. In testes, the lacI mutant frequency was increased at a single exposure level of 200 p.p.m. for 24 weeks. At 48 weeks, the lacI mutant frequency in testes was significantly increased to an equal degree at 25, 50 and 100 p.p.m. EO but not at 200 p.p.m. Analysis of the testes mutation spectrum in air control mice and in mice exposed to 200 p.p.m. EO for 48 weeks revealed that no single mutational type occurred at an increased frequency. In the testes, there was a small increase across all mutational types that was sufficient to increase the overall lacI mutation frequency although not significant individually. The mutation spectrum in testes of EO-exposed mice also revealed that the increased lacI mutant frequency observed at 25 or 50 p.p.m. EO was not due to an increase in mutant siblings (clonality). These data demonstrate that inhalation exposure to EO for up to 48 weeks produces distinct mutagenic responses in bone marrow and testes.

UI MeSH Term Description Entries
D008297 Male Males
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009152 Mutagenicity Tests Tests of chemical substances and physical agents for mutagenic potential. They include microbial, insect, mammalian cell, and whole animal tests. Genetic Toxicity Tests,Genotoxicity Tests,Mutagen Screening,Tests, Genetic Toxicity,Toxicity Tests, Genetic,Genetic Toxicity Test,Genotoxicity Test,Mutagen Screenings,Mutagenicity Test,Screening, Mutagen,Screenings, Mutagen,Test, Genotoxicity,Tests, Genotoxicity,Toxicity Test, Genetic
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D012097 Repressor Proteins Proteins which maintain the transcriptional quiescence of specific GENES or OPERONS. Classical repressor proteins are DNA-binding proteins that are normally bound to the OPERATOR REGION of an operon, or the ENHANCER SEQUENCES of a gene until a signal occurs that causes their release. Repressor Molecules,Transcriptional Silencing Factors,Proteins, Repressor,Silencing Factors, Transcriptional
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D004202 Disinfectants Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley's Condensed Chemical Dictionary, 11th ed) Biocide,Disinfectant,Biocides
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005027 Ethylene Oxide A colorless and flammable gas at room temperature and pressure. Ethylene oxide is a bactericidal, fungicidal, and sporicidal disinfectant. It is effective against most micro-organisms, including viruses. It is used as a fumigant for foodstuffs and textiles and as an agent for the gaseous sterilization of heat-labile pharmaceutical and surgical materials. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p794) Oxirane,Oxide, Ethylene
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol

Related Publications

Leslie Recio, and Maria Donner, and Diane Abernethy, and Linda Pluta, and Ann-Marie Steen, and Brian A Wong, and Arden James, and R Julian Preston
July 1997, Mutation research,
Leslie Recio, and Maria Donner, and Diane Abernethy, and Linda Pluta, and Ann-Marie Steen, and Brian A Wong, and Arden James, and R Julian Preston
August 1997, Mutation research,
Leslie Recio, and Maria Donner, and Diane Abernethy, and Linda Pluta, and Ann-Marie Steen, and Brian A Wong, and Arden James, and R Julian Preston
January 2001, Mutation research,
Leslie Recio, and Maria Donner, and Diane Abernethy, and Linda Pluta, and Ann-Marie Steen, and Brian A Wong, and Arden James, and R Julian Preston
March 1994, Carcinogenesis,
Leslie Recio, and Maria Donner, and Diane Abernethy, and Linda Pluta, and Ann-Marie Steen, and Brian A Wong, and Arden James, and R Julian Preston
June 1998, Mutation research,
Leslie Recio, and Maria Donner, and Diane Abernethy, and Linda Pluta, and Ann-Marie Steen, and Brian A Wong, and Arden James, and R Julian Preston
October 1996, Toxicology,
Leslie Recio, and Maria Donner, and Diane Abernethy, and Linda Pluta, and Ann-Marie Steen, and Brian A Wong, and Arden James, and R Julian Preston
January 1996, Environmental and molecular mutagenesis,
Leslie Recio, and Maria Donner, and Diane Abernethy, and Linda Pluta, and Ann-Marie Steen, and Brian A Wong, and Arden James, and R Julian Preston
January 1998, Environmental and molecular mutagenesis,
Leslie Recio, and Maria Donner, and Diane Abernethy, and Linda Pluta, and Ann-Marie Steen, and Brian A Wong, and Arden James, and R Julian Preston
November 1997, Carcinogenesis,
Leslie Recio, and Maria Donner, and Diane Abernethy, and Linda Pluta, and Ann-Marie Steen, and Brian A Wong, and Arden James, and R Julian Preston
January 1995, Environmental and molecular mutagenesis,
Copied contents to your clipboard!